Abstract
Objective: There is no standard consensus on a strategy in the second-line setting for gemcitabine refractory advanced pancreatic cancer. This study aimed to evaluate the activity and tolerability of oxaliplatin, irinotecan, 5-fluorouracil (5-FU) and leucovorin (FOLFIRINOX) as second-line therapy in locally advanced unresectable or metastatic pancreatic adenocarcinoma pretreated with gemcitabine based regimen. Methods: A retrospective survey was carried out with 18 patients (Eastern Cooperative Oncology Group performance status score of 0–1) with advanced pancreatic cancer who received a gemcitabine based chemotherapy and who were treated with FOLFIRINOX as second-line therapy between June 2011 and December 2012.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
